Literature DB >> 30958797

Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.

John Soltys1, Yiting Liu2, Alanna Ritchie2, Scott Wemlinger2, Kristin Schaller2, Hannah Schumann2, Gregory P Owens2, Jeffrey L Bennett1,2,3.   

Abstract

Neuromyelitis optica (NMO) is an autoimmune CNS disorder mediated by pathogenic aquaporin-4 (AQP4) water channel autoantibodies (AQP4-IgG). Although AQP4-IgG-driven complement-dependent cytotoxicity (CDC) is critical for the formation of NMO lesions, the molecular mechanisms governing optimal classical pathway activation are unknown. We investigated the molecular determinants driving CDC in NMO using recombinant AQP4-specific autoantibodies (AQP4 rAbs) derived from affected patients. We identified a group of AQP4 rAbs targeting a distinct extracellular loop C epitope that demonstrated enhanced CDC on target cells. Targeted mutations of AQP4 rAb Fc domains that enhance or diminish C1q binding or antibody Fc-Fc interactions showed that optimal CDC was driven by the assembly of multimeric rAb platforms that increase multivalent C1q binding and facilitate C1q activation. A peptide that blocks antibody Fc-Fc interaction inhibited CDC induced by AQP4 rAbs and polyclonal NMO patient sera. Super-resolution microscopy revealed that AQP4 rAbs with enhanced CDC preferentially formed organized clusters on supramolecular AQP4 orthogonal arrays, linking epitope-dependent multimeric assembly with enhanced C1q binding and activation. The resulting model of AQP4-IgG CDC provides a framework for understanding classical complement activation in human autoantibody-mediated disorders and identifies a potential new therapeutic avenue for treating NMO.

Entities:  

Keywords:  Complement; Demyelinating disorders; Immunoglobulins; Inflammation; Neuroscience

Mesh:

Substances:

Year:  2019        PMID: 30958797      PMCID: PMC6486354          DOI: 10.1172/JCI122942

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  77 in total

1.  Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Authors:  E O Saphire; P W Parren; R Pantophlet; M B Zwick; G M Morris; P M Rudd; R A Dwek; R L Stanfield; D R Burton; I A Wilson
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

2.  A statistically derived parameterization for the collagen triple-helix.

Authors:  Jan K Rainey; M Cynthia Goh
Journal:  Protein Sci       Date:  2002-11       Impact factor: 6.725

Review 3.  Structure and activation of the C1 complex of complement: unraveling the puzzle.

Authors:  Christine Gaboriaud; Nicole M Thielens; Lynn A Gregory; Véronique Rossi; Juan C Fontecilla-Camps; Gérard J Arlaud
Journal:  Trends Immunol       Date:  2004-07       Impact factor: 16.687

4.  Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.

Authors:  Puay-Wah Phuan; Julien Ratelade; Andrea Rossi; Lukmanee Tradtrantip; A S Verkman
Journal:  J Biol Chem       Date:  2012-03-05       Impact factor: 5.157

5.  Cloning the antibody response in humans with inflammatory CNS disease: isolation of measles virus-specific antibodies from phage display libraries of a subacute sclerosing panencephalitis brain.

Authors:  M P Burgoon; R A Williamson; G P Owens; O Ghausi; R B Bastidas; D R Burton; D H Gilden
Journal:  J Neuroimmunol       Date:  1999-02-01       Impact factor: 3.478

6.  Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.

Authors:  D B Drachman; C W Angus; R N Adams; J D Michelson; G J Hoffman
Journal:  N Engl J Med       Date:  1978-05-18       Impact factor: 91.245

7.  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Authors:  James F Howard; Kimiaki Utsugisawa; Michael Benatar; Hiroyuki Murai; Richard J Barohn; Isabel Illa; Saiju Jacob; John Vissing; Ted M Burns; John T Kissel; Srikanth Muppidi; Richard J Nowak; Fanny O'Brien; Jing-Jing Wang; Renato Mantegazza
Journal:  Lancet Neurol       Date:  2017-10-20       Impact factor: 44.182

Review 8.  The role of the complement system in acute kidney injury.

Authors:  James W McCullough; Brandon Renner; Joshua M Thurman
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

9.  Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; A S Verkman
Journal:  Mol Pharmacol       Date:  2013-04-09       Impact factor: 4.436

10.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

View more
  32 in total

Review 1.  Emerging therapeutic targets for neuromyelitis optica spectrum disorder.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; Alan S Verkman
Journal:  Expert Opin Ther Targets       Date:  2020-03-02       Impact factor: 6.902

2.  Microglia complement astrocytes in neuromyelitis optica.

Authors:  Zahra Moinfar; Scott S Zamvil
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.

Authors:  Tianjiao Duan; Lukmanee Tradtrantip; Puay-Wah Phuan; Jeffrey L Bennett; Alan S Verkman
Journal:  Neuropharmacology       Date:  2019-10-22       Impact factor: 5.250

Review 4.  The diverse and complex modes of action of anti-NMDA receptor autoantibodies.

Authors:  Lonnie P Wollmuth; Kelvin Chan; Laurent Groc
Journal:  Neuropharmacology       Date:  2021-05-31       Impact factor: 5.250

Review 5.  Autoantibodies in neurological disease.

Authors:  Harald Prüss
Journal:  Nat Rev Immunol       Date:  2021-05-11       Impact factor: 53.106

Review 6.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870

Review 7.  Role of B Cells in Multiple Sclerosis and Related Disorders.

Authors:  Giancarlo Comi; Amit Bar-Or; Hans Lassmann; Antonio Uccelli; Hans-Peter Hartung; Xavier Montalban; Per Solberg Sørensen; Reinhard Hohlfeld; Stephen L Hauser
Journal:  Ann Neurol       Date:  2020-11-04       Impact factor: 10.422

8.  Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder.

Authors:  Jie Li; Sam A Bazzi; Florian Schmitz; Hidetaka Tanno; Jonathan R McDaniel; Chang-Han Lee; Chaitanya Joshi; Jin Eyun Kim; Nancy Monson; Benjamin M Greenberg; Kristina Hedfalk; Esther Melamed; Gregory C Ippolito
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-06-24

Review 9.  Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.

Authors:  C Zografou; A G Vakrakou; P Stathopoulos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

10.  Comparative study of AQP4 antibody-related diseases and MOG antibody-related diseases among the population in Hunan, China.

Authors:  Xiqian Chen; Yijun Ren; Yiliu Zhang; Wei Lu
Journal:  Acta Neurol Belg       Date:  2020-07-31       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.